Quick Answer
Forte Biosciences, Inc. reported Operating Income Loss of -$70.66 million for the year ending 2025.
- Forte Biosciences, Inc. showed a decrease of -93.0% in Operating Income Loss from 2024 to 2025.
- This data is from Forte Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$7.57 million | Q2 2016: -$7.62 million | Q3 2016: -$8.53 million | Q1 2017: -$8.55 million | Q2 2017: -$8.65 million | Q3 2017: -$9.74 million | Q1 2018: -$12.85 million | Q2 2018: -$15.33 million | Q3 2018: $1.43 million | Q1 2019: -$16.87 million | Q2 2019: -$629.0 thousand | Q3 2019: -$684.0 thousand | Q1 2020: -$2.03 million | Q2 2020: -$34.75 million | Q3 2020: -$5.01 million | Q1 2021: -$4.74 million | Q2 2021: -$5.75 million | Q3 2021: -$7.70 million | Q1 2022: -$2.51 million | Q2 2022: -$3.02 million | Q3 2022: -$3.42 million | Q1 2023: -$6.86 million | Q2 2023: -$9.03 million | Q3 2023: -$10.22 million | Q1 2024: -$7.80 million | Q2 2024: -$12.82 million | Q3 2024: -$8.63 million | Q1 2025: -$16.12 million | Q2 2025: -$11.58 million | Q3 2025: -$18.38 million.
- Over the full 11 years of available data (2015 to 2025), Forte Biosciences, Inc.'s Operating Income Loss has declined by 207.8%.
- Historical annual values: Fiscal year 2025: -$70.66 million | Fiscal year 2024: -$36.60 million | Fiscal year 2023: -$32.49 million | Fiscal year 2022: -$13.90 million | Fiscal year 2021: -$21.49 million | Fiscal year 2020: -$46.28 million | Fiscal year 2019: -$4.06 million | Fiscal year 2018: -$45.85 million | Fiscal year 2017: -$37.63 million | Fiscal year 2016: -$31.69 million | Fiscal year 2015: -$22.95 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: